RT Journal Article
SR Electronic
T1 Serum Extracellular Vesicles Double-positive for CD9 and CD147 or for CD9 and CD63 Decrease After Surgical Resection in Patients With Colorectal Cancer: Potential Biomarkers of Residual Tumor
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2345
OP 2352
DO 10.21873/anticanres.18121
VO 46
IS 5
A1 ADACHI, YUKARI
A1 MATSUDA, TAKERU
A1 INUBUSHI, SACHIKO
A1 YASUDA, KEISUKE
A1 ITO, RYOTA
A1 SHIRAKAMI, NAOTO
A1 TACHIBANA, TAKAAKI
A1 IMAI, MASAKI
A1 KAGIYAMA, HIROKI
A1 TSUNEKI, TAKAO
A1 ANDO, MASAYUKI
A1 SAITO, MASAFUMI
A1 SUGITA, YUTAKA
A1 IKEDA, TARO
A1 KOTERAZAWA, YASUFUMI
A1 AOKI, TOMOAKI
A1 HARADA, HITOSHI
A1 OTOWA, YASUNORI
A1 URAKAWA, NAOKI
A1 GOTO, HIRONOBU
A1 HASEGAWA, HIROSHI
A1 KANAJI, SHINGO
A1 YAMASHITA, KIMIHIRO
A1 HOFFMAN, ROBERT M.
A1 KAKEJI, YOSHIHIRO
YR 2026
UL http://ar.iiarjournals.org/content/46/5/2345.abstract
AB Background/Aim: Extracellular vesicles (EVs), including exosomes, are abundant in body fluids, and EV surface proteins can be profiled as potential minimally invasive biomarkers. CD147 (EMMPRIN/Basigin) is a tumor-associated surface glycoprotein implicated in cancer progression. CD9 and CD63 are tetraspanin membrane proteins widely used as EV markers. The present study aimed to evaluate the clinical significance of serum EV subsets double-positive for CD9 and CD63, or for CD9 and CD147 in patients with colorectal cancer (CRC) before and after tumor resection.Materials and Methods: Sixteen patients with CRC were recruited, and paired pre- and postoperative serum samples were analyzed for CD9+ CD63+ EVs and CD9+ CD147+ EVs. Serum EVs were quantified using the ExoCounter system with antibody-conjugated beads. CD147 expression in resected tumor tissue was analyzed by immunohistochemistry.Results: CD9+ CD63+ EVs were significantly reduced in postoperative samples compared with preoperative samples (p=0.0151). CD9+ CD147+ EVs also showed a significant postoperative decrease (p=0.0186). CD147 immunostaining was positive in 13 out of 16 resected tumors (81.3%). In patients with CD147 negative tumors (n=3), serum CD9+ CD147+ EV levels were low at both pre- and postoperative time points and remained unchanged.Conclusion: Serum CD9+ CD63+ and CD9+ CD147+ EV subsets decreased after CRC surgery, supporting their potential utility as minimally invasive liquid biopsy biomarkers of postoperative tumor burden. Future prospective clinical trials will determine whether these EV subsets are indeed biomarkers of postoperative residual tumor.